Literature DB >> 28742550

Can Concurrent Abnormalities in Free Light Chains and Immunoglobulin Concentrations Identify a Target Population for Immunoglobulin Trials in Sepsis?

Manu Shankar-Hari1, Mervyn Singer, Jo Spencer.   

Abstract

OBJECTIVES: Light chains κ and λ are immunoglobulin constituents but also circulate independently in blood as free light chains. We investigated whether a concomitant abnormality in free light chain and immunoglobulin levels could identify a high risk of death sepsis subpopulation to inform future IV immunoglobulin trials. We tested whether light chain allelic inclusion occurs in circulating B cells.
DESIGN: Prospective cohort study.
SETTING: Adult general ICUs. PATIENTS: Adult sepsis patients without any documented immune comorbidity.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Serum total free light chain, immunoglobulin G, immunoglobulin A, and immunoglobulin M were measured on ICU days 1, 3, and 7. Population normal ranges defined normal and abnormal categories. Logistic regression models tested any independent relationship between high free light chain, immunoglobulins and hospital mortality. CD19 B-cell subsets expressing cell surface κ and λ were quantified by flow cytometry; their frequencies were compared against healthy subjects and correlation assessed against free light chain concentrations. On ICU day 1, high free light chain λ and high free light chain κ were seen in 46.5% and 75.3% of the study cohort (n = 101). Low immunoglobulin levels were commonplace (45.5%) at ICU admission. ICU admission day free light chain and immunoglobulin concentrations were significantly correlated. Septic patients had significantly more CD19 B cells expressing both κ and λ compared with healthy controls (median [interquartile range] 4.1% [2.4-11.0] vs 1.3% [1.2-2.9], respectively; p = 0.0001); these correlated with free light chain concentrations.
CONCLUSIONS: To our knowledge, abnormalities and associations of free light chain in critically ill adults with sepsis have not been previously reported. The additional prognostic value of free light chain λ and the significance of allelic inclusion in B cells in sepsis require further investigation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28742550     DOI: 10.1097/CCM.0000000000002627

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

Review 1.  Immunoglobulins and sepsis.

Authors:  Manu Shankar-Hari; Martin Bruun Madsen; Alexis F Turgeon
Journal:  Intensive Care Med       Date:  2018-01-18       Impact factor: 17.440

2.  Victims or Culprits, B Cells May Serve as Markers for Mortality Risk and Targeted Therapy in Sepsis.

Authors:  Zoltán Spolarics
Journal:  Crit Care Med       Date:  2017-11       Impact factor: 7.598

3.  Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study.

Authors:  Julie K Wilson; Yuan Zhao; Mervyn Singer; Jo Spencer; Manu Shankar-Hari
Journal:  Crit Care       Date:  2018-04-17       Impact factor: 9.097

4.  Kinetics of Immunoglobulins in Septic Shock Patients Treated With an IgM- and IgA-Enriched Intravenous Preparation: An Observational Study.

Authors:  Giorgio Berlot; Alice Scamperle; Tatiana Istrati; Roberto Dattola; Irene Longo; Antonino Chillemi; Silvia Baronio; Giada Quarantotto; Silvia Zanchi; Erik Roman-Pognuz; Mattia Bixio; Ariella Tomasini
Journal:  Front Med (Lausanne)       Date:  2021-03-01

Review 5.  Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View.

Authors:  Dominik Jarczak; Stefan Kluge; Axel Nierhaus
Journal:  Int J Mol Sci       Date:  2020-08-03       Impact factor: 5.923

6.  Correlation of Immunoglobulins and Lymphocytes Levels With the Clinical and Microbiological Response of Septic Patients With Gram-Negative Bacteremia.

Authors:  Diamanto Aretha; Katerina Leukaditou; Fotini Fligou; Karolina Akinosoglou; Alexandros Spyridonidis; Alexandra Nikolopoulou; Stelios F Assimakopoulos
Journal:  J Clin Med Res       Date:  2021-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.